Radiopharmaceutical Deal Benchmarks
Market Analysis
Radiopharmaceuticals have emerged as one of the fastest-growing modalities in oncology deal-making. Phase 1 radiopharmaceutical deals carry a median total deal value of $4.1B, with upfronts averaging $412M. The significant premium reflects constrained supply of radioisotopes, specialized manufacturing requirements, and the theranostic potential that enables patient selection via companion diagnostics.
The milestone structure for radiopharmaceutical deals allocates $1.5B to development milestones, recognizing the significant de-risking needed around dosimetry, manufacturing scale-up, and supply chain security for isotopes such as actinium-225 and lutetium-177. Commercial milestones of $921M reward the blockbuster trajectory demonstrated by approved RPTs.
Royalty rates range from 10.4% to 19.4%, with high-tier escalation to 23.4%. The constrained competitive landscape and high barriers to entry for radiopharmaceutical manufacturing give licensors strong negotiating leverage in these transactions.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
Why are radiopharmaceutical deals so highly valued?
What are the key risk factors in radiopharmaceutical licensing?
How do radiopharmaceutical royalty rates compare to other modalities?
What milestone structure is typical for RPT deals?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.